←
Drew T Bergman, MD240 posts
Drew T Bergman, MD avatar✓

Drew T Bergman, MD ✓

@dtbergman

Radiation oncology resident @MSK_RadOnc | PGY-1 @newtonwellesley @MassGenBrigham | MD @GeiselMed @dartmouth | Married to @AlexaRiobueno | He/him

◷ Joined August 2012▧ 24 Photos and videos
Xiangmeng(Shawn) Cai avatar
⟳ Drew T Bergman, MD retweeted
Xiangmeng(Shawn) Cai@XiangmengCai·Oct 9

Have you ever looked at a gene in IGV or a genome browser and wondered “What are all those (ATAC-seq/H3K27ac/CTCF ChIP-seq/…) peaks doing?” 🤔 I’m thrilled to share that we developed a new technology called Swap-seq to answer that exact question. biorxiv.org/content/10.64898…

Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

Much more in the paper! Next from this registry: tumor volume, lesion-level local control, and radiation necrosis.

Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

These are retrospective outcomes in patients selected for SRS, and salvage patterns reflect our practice. They provide contemporary benchmarks supporting individualized SRS decisions guided by clinical factors and institutional expertise beyond a fixed lesion-count cutoff.

Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

What predicted salvage WBRT in an adjusted model? ↑ Higher lesion burden, breast & small-cell lung primaries ↓ Age ≥70 & more recent treatment era These associations reflect both disease and treatment-selection patterns.

Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

One finding that stood out: the SRS-first pattern continued through salvage. After a SECOND SRS course, 24-month cumulative incidence was: 🎯 Third SRS: 41.7% • Salvage WBRT: 6.7% Further radiation treatment remained predominantly focal.

Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

What happened after SRS? Salvage WBRT was uncommon. Among patients without prior WBRT, 24-month cumulative incidence was: • 1 lesion: 4.5% • 2–4: 5.5% • ≥5: 7.3% Risk increased with burden, but absolute use remained low, accounting for competing mortality.

Post attachment
Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

We argue that the decision to treat with upfront SRS should be based on first-principles rather than strict thresholds, as there’s more to prognosis than counting lesions. PS, extracranial disease, histology, and CNS-active systemic therapy matter (not 🚀 science!).

Post attachment
Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

For 11–20 vs 5–10 lesions, adjusted HR was 1.04 (95% CI 0.86–1.27), meeting the 1.30 non-inferiority margin in a post hoc analysis. Beyond 20? Still an open question. Only 41 patients, and non-inferiority was not established. More to come!

Post attachment
Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

Building on Yamamoto et al and others, we found a familiar pattern in the modern systemic-therapy era and in a more diverse group of cancer types beyond NSCLC: survival plateaued from 5–20 lesions. Median OS: • 1: 16.2 months • 2–4: 11.0 • 5–10: 8.2 • 11–20: 8.7

Post attachment
Drew T Bergman, MD avatar
Drew T Bergman, MD@dtbergman·Oct 8

Evidence for upfront SRS with higher lesion ceilings is mounting, an approach we've favored over WBRT for years @MSK_RadOnc. We assembled 3,893 consecutive patients across 7 sites from 2017–2026, to our knowledge the largest contemporary linac-based SRS cohort reported to date.